Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 7/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14193254 | 0.88 | EPHX1 (0.49) | EPHX1MEN1GAAKMT2AACHE | |
| SCHEMBL12787604 | 0.82 | EPHX1 (0.59) | EPHX1MEN1GAAKMT2AACHE | |
| SCHEMBL23843222 | 0.81 | EPHX1 (0.62) | EPHX1MEN1GAAKMT2AACHE | |
| SCHEMBL14980080 | 0.81 | ACACB (0.34) | EPHX1 | |
| SCHEMBL277468 | 0.81 | ACHE (0.44) | EPHX1ACHEALOX15 | |
| SCHEMBL13932170 | 0.80 | ACHE (0.49) | ACHE | |
| SCHEMBL902008 | 0.80 | MEN1 (0.59) | MEN1GAAKMT2ATDP1 | |
| SCHEMBL10140672 | 0.80 | MEN1 (0.59) | MEN1GAAKMT2ATDP1 | |
| SCHEMBL7252127 | 0.79 | EPHX1 (0.77) | EPHX1MEN1KMT2AACHETDP1 | |
| SCHEMBL14063726 | 0.79 | EPHX1 (0.50) | EPHX1MEN1GAAKMT2AACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9175060-B2 | PEG modified exendin or exendin analog and compositions and use thereof | SHANGHAI BENEMAE PHARMACEUTICAL CORPORATION (CN) | 2015-11-03 | — | — | US | disclosed |
| US-8835556-B2 | Hydrolytically stable maleimide-terminated polymers | NEKTAR THERAPEUTICS (US) | 2014-09-16 | — | — | US | disclosed |
| US-8304511-B2 | Maleamic acid polymer derivatives and their bioconjugates | NEKTAR THERAPEUTICS (US) | 2012-11-06 | — | — | US | disclosed |
| US-20120226022-A1 | HYDROLYTICALLY STABLE MALEIMIDE-TERMINATED POLYMERS | NEKTAR THERAPEUTICS (US) | 2012-09-06 | — | — | US | disclosed |
| US-8227555-B2 | Hydrolytically stable maleimide-terminated polymers | NEKTAR THERAPEUTICS (US) | 2012-07-24 | — | — | US | disclosed |
| US-8076412-B2 | Water-soluble polymer alkanals | NEKTAR THERAPEUTICS (US) | 2011-12-13 | — | — | US | disclosed |
| US-20110262379-A1 | Maleamic Acid Polymer Derivatives and Their Bioconjugates | NEKTAR THERAPEUTICS (US) | 2011-10-27 | — | — | US | disclosed |
| US-20110034737-A1 | Water-Soluble Polymer Alkanals | NEKTAR THERAPEUTICS (US) | 2011-02-10 | — | — | US | disclosed |
| US-20100240586-A1 | PEG MODIFIED EXENDIN OR EXENDIN ANALOG AND COMPOSITIONS AND USE THEREOF | SHANGHAI HUAYI BIO-LAB CO., LTD. (CN) | 2010-09-23 | — | — | US | disclosed |
| US-7511094-B2 | 2-methylbutyraldehyde diethyl acetal end capped polyoxyethylene glycol; polyalkylene oxide, polyivnylpyrrolidone, polyvinyl alcohol, polyoxazoline etc. endcapped with polyetherpolyamine copolymers or oligomers covalently attached to diacetal tetramethylene group | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2009-03-31 | — | — | US | disclosed |
| US-7432331-B2 | Hydrolytically stable maleimide-terminated polymers | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2008-10-07 | — | — | US | disclosed |
| US-7432330-B2 | Hydrolytically stable maleimide-terminated polymers | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2008-10-07 | — | — | US | disclosed |
| US-7329721-B2 | Maleamic acid polymer derivatives and their bioconjugates | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2008-02-12 | — | — | US | disclosed |
| US-7157546-B2 | Polyoxyethylene glycol; purity, storage stability | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2007-01-02 | — | — | US | disclosed |
| US-5773643-A | Process for preparation of isocyanate compounds | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 1998-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110262379-A1 | Maleamic Acid Polymer Derivatives and Their Bioconjugates | PCMT1, SUMO3, PTMA | EPHX1 4347/4885MEN1 225/4885GAA 2307/4885 |
| US-20120226022-A1 | HYDROLYTICALLY STABLE MALEIMIDE-TERMINATED POLYMERS | PADI6, MPI, VIM | EPHX1 2848/4885MEN1 70/4885GAA 224/4885 |
| US-20110034737-A1 | Water-Soluble Polymer Alkanals | ALK, ALKBH3, AQP1 | EPHX1 290/4885MEN1 4247/4885GAA 155/4885 |
| US-20100240586-A1 | PEG MODIFIED EXENDIN OR EXENDIN ANALOG AND COMPOSITIONS AND USE THEREOF | GCG, GLP1R, NGLY1 | EPHX1 623/4885MEN1 225/4885GAA 725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.